Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • US firms approach USTR...

    US firms approach USTR against Indias medical price control measures

    Written by Ruby Khatun Khatun Published On 2017-10-22T09:58:31+05:30  |  Updated On 22 Oct 2017 9:58 AM IST
    US firms approach USTR against Indias medical price control measures

    Washington: American companies producing medical devices and health information systems have approached the US Trade Representative against India's move to implement price controls on coronary stents and knee replacement implants that they say denying them equitable market access.


    In a petition, the Advanced Medical Technology Association (AdvaMed) president and CEO Scott Whitaker requested the US Trade Representative (USTR) to "suspend or withdraw" India's benefits under Generalised System of Preferences (GSP).


    "AdvaMed and its members are deeply concerned about recently implemented price controls on coronary stents and knee replacement implants in India that have slashed prices by as much as 85 percent and 70 percent, respectively, followed by signals that price caps for additional life-saving and life-improving medical devices may be forthcoming," Scott said.


    Scott said that their intention was not for India to lose the benefits of GSP, but rather to advance engagement and meaningful discussions on restoring market access for medtech in India while keeping patients interests at the center of all discussions.


    Scott alleged that India's focus on controlling prices of high-quality medical devices, without any attempt to address the larger picture and correct inefficiencies in the health care system, would not achieve its intended benefits.


    Recent reports indicate that the lowering of prices on medical devices which are only one component of overall procedure costs are not being passed along to patients.


    Price controls may also block innovations and limit patient access to the best available care, he said.


    Scott warned that failure to implement a mutually acceptable alternative could deter global organizations from making their latest products available to India s health care providers and patients, make Indian innovators less competitive in global markets, negatively impact future investment in India, and ultimately harm patients.


    "We believe a stable and predictable market environment is key to driving investments in R&D, manufacturing, and other services to grow the medical technology industry in India and meet the current and future needs of all of India's people," he said.

    AdvaMedAdvanced Medical Technology AssociationAmerican companiesCoronary StentsIndiaknee replacement implantsMedical Devicesmedical price control measuresmedical technology industryprice controlsUSUS firmsUS Trade RepresentativeUSTR
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok